Mitomycin Exhibits Durable Responses in Recurrent, Low-Grade NMIBC

Mitomycin Exhibits Durable Responses in Recurrent, Low-Grade NMIBC

Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Intravesical Mitomycin Produces 24-Month Response in Recurrent NMIBC

New data showed a 72.2% DOR rate in patients with recurrent low-grade, intermediate-risk non–muscle-invasive bladder cancer who had a CR at 3 months.

Durable Efficacy of Intravesical Mitomycin Confirmed in Phase 3 Trial for NMIBC

UroGen Pharma's ENVISION trial reveals promising long-term efficacy of intravesical mitomycin for treating low-grade bladder cancer, offering a non-surgical option.

Updated EVISION data show sustained efficacy of mitomycin intravesical solution for LG-IR-NMIBC

Treatment with mitomycin for intravesical solution led to a 24-month DOR of 72.2% among patients who achieved an initial complete response.